Table 1.
Characteristics of Adults 65 Years and Older with Atrial Fibrillation, Weighted to Estimate National Prevalence, 2014
| Characteristic | Prevalence (95% CI) (n = 779) |
|---|---|
| Sociodemographics | |
| Age, median (IQR), y | 80 (74–86) |
| Women, % | 50 (46–54) |
| Married or partnered, % | 51 (47–55) |
| Lives alone, % | 35 (31–39) |
| Education, % | |
| Less than high school | 17 (13–20) |
| Completed high school | 54 (50–59) |
| More than high school | 29 (25–33) |
| Race, % | |
| White | 93 (91–95) |
| Black | 4 (2–5) |
| Other | 4 (2–5) |
| Hispanic ethnicity, % | 2 (1–5) |
| Proxy interview, % | 9 (7–12) |
| Nursing home residence, % | 6 (7–9) |
| Medical comorbidities, % | |
| Self-reported health (fair or poor) | 45 (41–48) |
| Depressive symptoms | 14 (11–17) |
| Congestive heart failure | 32 (29–36) |
| Hypertension | 76 (72–80) |
| Stroke | 25 (21–29) |
| Diabetes mellitus | 33 (29–38) |
| Myocardial infarction | 30 (26–33) |
| Angina | 29 (26–33) |
| Lung disease | 19 (16–22) |
| Cancer, excluding skin cancer | 28 (25–32) |
| Atrial fibrillation | |
| CHA2DS2-VASc score, %a | |
| 1 | 1 (0–3) |
| 2 | 8 (6–11) |
| 3 | 19 (16–22) |
| 4 | 21 (17–25) |
| 5 | 21 (18–24) |
| 6 | 16 (14–19) |
| 7 | 9 (6–11) |
| 8 | 4 (2–5) |
| 9 | 1 (0–2) |
| CHA2DS2-VASc score, median (IQR) | 4 (3–5) |
| 2014 Guidelines recommend anticoagulant use, %b | 99 (97–99) |
| 2019 Guidelines recommend anticoagulant use, %c | 97 (96–99) |
| Anticoagulant use, % | 65 (61–70) |
Note: Percentages shown are weighted using the Health and Retirement Study–RAND survey weights to estimate prevalence among adults 65 years and older with atrial fibrillation in the United States.
Abbreviations: CHA2DS2-VASc score, congestive heart failure/hypertension/age/diabetes mellitus/stroke/vascular disease; CI, confidence interval; IQR, interquartile range.
None with CHA2DS2-VASc score of 0.
Based on 2014 American Heart Association/American College of Cardiology/Health and Retirement Study consensus guidelines: recommended anticoagulation for all with a CHA2DS2-VASc score of 2 or greater.
Based on 2019 American Heart Association/American College of Cardiology/Health and Retirement Study consensus guidelines: recommended anticoagulation for men with CHA2DS2-VASc score of 2 or greater and women with CHA2DS2-VASc score of 3 or greater.